Dr. Patrick W. Serruys and colleagues at Erasmus Medical Center in Rotterdam
analyzed 2-year outcomes of 708 patients with diabetes mellitus enrolled in
the RESEARCH and T-SEARCH registries. One in four of the diabetics were insulin-dependent.
The patients received a bare-metal stent, a paclitaxel-eluting stent or a sirolimus-eluting
stent to open occluded coronary vessels.
The investigators report that the relative risk for target vessel revascularization
and major adverse events was not significantly different in the paclitaxel-eluting
stent compared with the bare-metal stent, after adjusting for independent predictors
of adverse events.
The paclitaxel-eluting stent had a non-significant lower incidence of target
vessel revascularization and major adverse events compared with sirolimus-eluting
stent in non-insulin-dependent diabetics at 2 years. The rate of adverse events
was higher with sirolimus-eluting stent at 1 year.
The 2-year cumulative mortality was comparable in all three groups. However,
mortality rate during the second year was 5.8% in the sirolimus-eluting stent
group compared with 1.2% in the paclitaxel-eluting stent group (p = 0.007).
The investigators observed that the incidence of stent thrombosis was 4.4%
in the sirolimus-eluting stent group compared with 2.4% in the paclitaxel-eluting
stent group and 0.8% in patients who received bare metal stents. The higher
mortality rate with sirolimus-eluting stent may be related to the increased
incidence of stent thrombosis in patients treated with the sirolimus-eluting
stent.
The Dutch team notes that, overall, "there was no significant difference
between sirolimus-eluting stent and paclitaxel-eluting stent in each of the
clinical endpoints, and neither in the non-insulin-dependent diabetes mellitus
group, which are hypothesized to be better off with paclitaxel-eluting stent."
"The present study suffers from the inherent limitations of a non-randomized
trial," Dr. Serruys' team notes. "More larger-scale and randomized
trials are needed to elucidate the best treatment for patients with diabetes
mellitus and the possible superiority of one drug-eluting stent compared to
another, also taking into account the long-term adverse events like stent thrombosis,"
the Dutch investigators conclude.
As reported in the January issue of the European Heart Journal. However, the
question of whether one drug-eluting stent is superior to the other remains
unclear.
Eur Heart J 2007;28:26-32.
================================
Start your own walking program
New StepTracker Available at special prices. See the results of the Step Program
Study.
http://www.diabetesincontrol.com/programs/steps/index.shtml
Purchase your own pedometers and receive the Steps to Health Program at no charge.
http://www.rx4betterhealth.com/steptracker/
The Only Pedometer on the Market That Comes With a Program for Success!
================================
DID YOU KNOW:
What Prevents Doctors from Counseling Their Patients to Lose Weight, Exercise,
Quit Smoking?: Ninety-nine percent of doctors believe that part of their job
is to encourage their patients to live a healthier lifestyle, but only 20% actually
do it. Research at the University of Haifa addresses the question: why not?
See this week’s Item #6
|